RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Concert Pharmaceuticals - Stock

Concert Pharmaceuticals Revenue 2024

Concert Pharmaceuticals Revenue

32.38 M USD

Ticker

CNCE

ISIN

US2060221056

WKN

A1XEAC

In 2024, Concert Pharmaceuticals's sales reached 32.38 M USD, a 146.85% difference from the 13.12 M USD sales recorded in the previous year.

The Concert Pharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2028e393.58-
2027e280.94-
2026e195.14-
2025e98.28-
2024e32.38-
2023e13.12-
2022e0.1-
202132.58-
20207.9-
20191.1-
201810.5-
2017143.9-
20160.2-
201566.7-
20148.6-
201325.4-
201212.8-
201119.5-

Concert Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Concert Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Concert Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Concert Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Concert Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Concert Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Concert Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Concert Pharmaceuticals’s growth potential.

Concert Pharmaceuticals Revenue, Profit, and EBIT History

DateConcert Pharmaceuticals RevenueConcert Pharmaceuticals EBITConcert Pharmaceuticals Net Income
2028e393.58 M undefined0 undefined80.58 M undefined
2027e280.94 M undefined78.9 M undefined34.04 M undefined
2026e195.14 M undefined3.77 M undefined1.22 M undefined
2025e98.28 M undefined-79.06 M undefined-40.17 M undefined
2024e32.38 M undefined-129.49 M undefined-101.39 M undefined
2023e13.12 M undefined-137.33 M undefined-134.31 M undefined
2022e101,745 undefined-123.74 M undefined-135.59 M undefined
202132.58 M undefined-77.51 M undefined-80.05 M undefined
20207.9 M undefined-72.6 M undefined-74.8 M undefined
20191.1 M undefined-79 M undefined-78.2 M undefined
201810.5 M undefined-55.6 M undefined-56 M undefined
2017143.9 M undefined92.6 M undefined95.2 M undefined
2016200,000 undefined-51.2 M undefined-50.7 M undefined
201566.7 M undefined24.8 M undefined24.2 M undefined
20148.6 M undefined-30.6 M undefined-31.8 M undefined
201325.4 M undefined-4.4 M undefined-6.5 M undefined
201212.8 M undefined-18.6 M undefined-20.8 M undefined
201119.5 M undefined-11.3 M undefined-12.4 M undefined

Concert Pharmaceuticals stock margins

The Concert Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Concert Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Concert Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Concert Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Concert Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Concert Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Concert Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Concert Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Concert Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Concert Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Concert Pharmaceuticals Margin History

Concert Pharmaceuticals Gross marginConcert Pharmaceuticals Profit marginConcert Pharmaceuticals EBIT marginConcert Pharmaceuticals Profit margin
2028e0 %0 %20.47 %
2027e0 %28.08 %12.12 %
2026e0 %1.93 %0.63 %
2025e0 %-80.44 %-40.87 %
2024e0 %-399.92 %-313.15 %
2023e0 %-1,046.99 %-1,023.95 %
2022e0 %-121,614.29 %-133,259.7 %
20210 %-237.92 %-245.72 %
20200 %-918.99 %-946.84 %
20190 %-7,181.82 %-7,109.09 %
20180 %-529.52 %-533.33 %
20170 %64.35 %66.16 %
20160 %-25,600 %-25,350 %
20150 %37.18 %36.28 %
20140 %-355.81 %-369.77 %
20130 %-17.32 %-25.59 %
20120 %-145.31 %-162.5 %
20110 %-57.95 %-63.59 %

Concert Pharmaceuticals Aktienanalyse

What does Concert Pharmaceuticals do?

Concert Pharmaceuticals Inc was founded in 2006 and is based in Lexington, Massachusetts. The company is engaged in the discovery and development of innovative drugs for the treatment of serious diseases. The goal is to explore and bring to market novel therapeutic approaches to help people with medical needs. The company has a unique business model that focuses on the use of patented deuterosome technologies and other proprietary methods. These technologies allow Concert Pharmaceuticals to modify and alter the properties of existing drugs. This enables the development of new products that either have higher efficacy or produce fewer adverse effects in patients. One of Concert Pharmaceuticals' key areas is neurological disorders. Here, the company focuses its research on the treatment of diseases such as Alzheimer's, schizophrenia, depression, and pain. In addition, Concert Pharmaceuticals also has projects in other areas, such as the treatment of respiratory diseases, cancer, or metabolic disorders. One of the best-known products of Concert Pharmaceuticals is the drug CTP-543 for the treatment of alopecia areata or patchy hair loss. The condition, which causes sudden and massive hair loss, can be very distressing and poses a major challenge, as there is currently no effective treatment method known. CTP-543 was designated as an orphan drug by the FDA (Food and Drug Administration) in the United States in 2020. This means that it is a drug that is used to treat a rare disease and is financially supported by the FDA. The company hopes that the medication will soon be available on the market and can help those affected to improve their quality of life. Concert Pharmaceuticals also has a collaboration with Celgene Corporation, an internationally active biotechnology company. Together, they aim to develop drugs that can help in the treatment of cancer. This collaboration is intended to accelerate scientific and technological advancements. The goal is to help patients faster and more effectively. Overall, Concert Pharmaceuticals employs around 120 people and has a number of patents and scientific publications to its name in recent years. The company collaborates with many renowned institutions and research facilities worldwide to find the best possible solutions in drug development. In summary, Concert Pharmaceuticals Inc is a very innovative company in the field of drug development. In addition to neurological research, the company also has projects in other areas. With its unique business model and the use of patented technologies, Concert Pharmaceuticals has the potential to develop new and effective drugs in the future, thereby improving the lives of many people worldwide. Concert Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Concert Pharmaceuticals's Sales Figures

The sales figures of Concert Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Concert Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Concert Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Concert Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Concert Pharmaceuticals Stock

How much revenue did Concert Pharmaceuticals generate this year?

Concert Pharmaceuticals has achieved a revenue of 32.38 M USD this year.

How much was the turnover of the company Concert Pharmaceuticals compared to the previous year?

The revenue of Concert Pharmaceuticals has increased by 146.85% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Concert Pharmaceuticals?

The revenue of Concert Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Concert Pharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Concert Pharmaceuticals so important for investors?

The revenue of Concert Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Concert Pharmaceuticals pay?

Over the past 12 months, Concert Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Concert Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Concert Pharmaceuticals?

The current dividend yield of Concert Pharmaceuticals is .

When does Concert Pharmaceuticals pay dividends?

Concert Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Concert Pharmaceuticals?

Concert Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Concert Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Concert Pharmaceuticals located?

Concert Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Concert Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Concert Pharmaceuticals from 6/14/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/14/2024.

When did Concert Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/14/2024.

What was the dividend of Concert Pharmaceuticals in the year 2023?

In the year 2023, Concert Pharmaceuticals distributed 0 USD as dividends.

In which currency does Concert Pharmaceuticals pay out the dividend?

The dividends of Concert Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Concert Pharmaceuticals

Our stock analysis for Concert Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Concert Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.